Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma

被引：0
|
作者：
Kefford, R.
Millward, M.
Hersey, P.
Brady, B.
Graham, M.
Johnson, R. G.
Hannah, A. L.
机构：
[1] Westmead Hosp, Wentworthville, Australia
[2] Sir Charles Gairdner Hosp, Nedlands, WA, Australia
[3] Univ WA, Nedlands, WA, Australia
[4] Univ Newcastle, Newcastle, NSW, Australia
[5] Cabrini Hlth Private Hosp, Malvern, Australia
[6] Kosan Biosci, Hayward, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8558
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T).
    Modi, S.
    Stopeck, A.
    Gordon, M. S.
    Solit, D.
    Ma, W.
    Wheler, J.
    Cropp, G.
    Johnson, R. G.
    Hannah, A. L.
    Hudis, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 3S - 3S
  • [2] Prevention and treatment of bortezomib-induced peripheral neuropathy by the Hsp90 inhibitor tanespimycin (KOS-953) in the rat
    Zhong, Z.
    Simmons, J.
    Timmermans, P.
    EJC SUPPLEMENTS, 2008, 6 (12): : 49 - 49
  • [3] Phase 1 dose escalating trial of KOS-953 (heat shock protein 90 inhibitor) and trastuzumab (T)
    Modi, Shanu
    Stopeck, Alison T.
    Gordon, Michael S.
    Solit, David
    Bagatell, Rochelle
    Ma, Weining
    Wheler, Jennifer
    Cropp, Gillian F.
    Rosen, Neal
    Johnson, Robert G., Jr.
    Hannah, Alison L.
    Hudis, Clifford
    CANCER RESEARCH, 2006, 66 (08)
  • [4] Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma
    Duus, J.
    Bahar, H. I.
    Venkataraman, G.
    Ozpuyan, F.
    Izban, K. F.
    Al-Masri, H.
    Maududi, T.
    Toor, A.
    Alkan, S.
    LEUKEMIA & LYMPHOMA, 2006, 47 (07) : 1369 - 1378
  • [5] Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma
    Oki, Yasuhiro
    Copeland, Amanda
    Romaguera, Jorge
    Fayad, Luis
    Fanale, Michelle
    Faria, Silvana de Castro
    Medeiros, L. Jeffrey
    Ivy, Percy
    Younes, Anas
    LEUKEMIA & LYMPHOMA, 2012, 53 (05) : 990 - 992
  • [6] Secreted heat shock protein-90 (Hsp90) in wound healing and cancer
    Li, Wei
    Sahu, Divya
    Tsen, Fred
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2012, 1823 (03): : 730 - 741
  • [7] Histologic and functional analysis of heat shock protein-90 (HSP90) in multiple myeloma
    Duus, J
    Venkataraman, G
    Bahar, HI
    Izban, KF
    Al-Masri, H
    Maududi, T
    Toor, A
    Alkan, S
    MODERN PATHOLOGY, 2006, 19 : 223A - 223A
  • [8] Histologic and functional analysis of heat shock protein-90 (HSP90) in multiple myeloma
    Duus, J
    Venkataraman, G
    Bahar, HI
    Izban, KF
    Al-Masri, H
    Maududi, T
    Toor, A
    Alkan, S
    LABORATORY INVESTIGATION, 2006, 86 : 223A - 223A
  • [9] Pharmacokinetics (PK) and toxicology of KOS-1022, an orally administered heat shock protein 90 (HSP90) Inhibitor
    Kersey, Kathryn
    Zhong, Ziyang
    Craig, Darren
    Feng, Lisa
    Lin, Lee-Juian
    Sherrill, Mike
    Timmermans, Pieter
    Hannah, Alison L.
    Johnson, Robert G., Jr.
    CANCER RESEARCH, 2006, 66 (08)
  • [10] Anti-tumor activity of KOS-953, a cremophor-based formulation of the hsp90 inhibitor 17-AAG
    Mitsiades, CS
    Mitsiades, N
    Rooney, M
    Hideshima, T
    Chauhan, D
    Munshi, NC
    Johnson, R
    Hannah, A
    Richardson, PG
    Anderson, KC
    BLOOD, 2004, 104 (11) : 660A - 661A
12345